Premium
HLA class II gene polymorphism contributes little to Hashimoto's thyroiditis
Author(s) -
Jenkins David,
Penny Michelle A.,
Fletcher Jeremy A.,
Jacobs Karen H.,
Mijovic Catherine H.,
Franklyn Jayne A.,
Sheppard Michael C.
Publication year - 1992
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1992.tb02298.x
Subject(s) - thyroiditis , human leukocyte antigen , restriction fragment length polymorphism , medicine , immunology , allele , polymorphism (computer science) , disease , genotype , antigen , genetics , biology , gene
Previous studies of HLA and Hashimoto's thyroiditis have shown weak associations between the disease and various HLA‐DR antigens. OBJECTIVE To define better the contribution of HLA class II alleles to susceptibility to Hashimoto's thyroiditis. DESIGN AND MEASUREMENTS Comparison of HLA‐DRB, DQA and DQB restriction fragment length polymorphisms in patients with Hashimoto's thyroiditis and control subjects, and meta‐analysis of this and other published studies. PATIENTS Fifty Caucasian patients with Hashimoto's thyroiditis and 93 racially‐matched control subjects. RESULTS A 4.6 kb Taq 1 DQA restriction fragment length polymorphism occurred in 60% of patients compared with 35.5% of controls, P c < 0.025. No other restriction fragment length polymorphism was significantly associated with the disease. Meta‐analysis of several studies demonstrated weak, positive associations between the disease and DR3 and DR4. An association with DR5 was not significant. CONCLUSIONS DR antigens are unlikely to determine disease susceptibility directly. These findings indicate that any contribution of HLA genes to inherited susceptibility to Hashimoto's thyroiditis is small and requires confirmation in family studies. We thank Professor R. Thompson for assaying antibody litres, and Professor P. A. Peterson for the gift of the cDNA clones. DJ was supported by Eli Lilly (UK), MAP by the Medical Research Council (UK), KHJ by the British Diabetic Association, CHM by the Wellcome Trust.